ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
Chromosomal rearrangements involving erythroblast transformation specific (ETS) family transcription factors were recently defined as the most common genetic alterations in human prostate cancer. Despite their prevalence, it is unclear what quantitative role they play in either initiation or progression of the disease. Using a lentiviral transduction and dissociated cell prostate regeneration approach, we find that acutely increased expression of ETS proteins in adult murine prostate epithelial cells is sufficient to induce the formation of epithelial hyperplasia and focal prostatic intraepithelial neoplasia (PIN) lesions, but not progression to carcinoma. However, combined expression of ERG with additional genetic alternations associated with human prostate cancer can lead to aggressive disease. Although ERG overexpression does not cooperate with loss of the tumor suppressor p53, it does collaborate with alterations in PI3K signaling, such as Pten knockdown or AKT up-regulation, to produce a well-differentiated adenocarcinoma. Most striking is our finding that overexpression of androgen receptor (AR) does not give rise to any hyperplastic lesions, but when combined with high levels of ERG, it promotes the development of a more poorly differentiated, invasive adenocarcinoma. These findings suggest that in human prostate cancer, the most potent function of ETS gene fusions may be to synergize with alternative genetic events and provide different pathways for carcinoma production and invasive behavior. Our results provide direct evidence for selective cooperating events in ERG-induced prostate tumorigenesis and offer a rational basis for combined therapeutic interventions against multiple oncogenic pathways in prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, the genetic finding that ETS and AR genes cooperate in oncogenesis (175) indicates that this mechanism is more complex than our current understanding and may differ on a target-by-target basis (180).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [175]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 2×
“But the cells must accumulate several other rate-limiting mutations over a long period to become malignant (2).”
BackgroundResultRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 2×
“AR is commonly mutated or amplified in human PCa (3, 35), and the AR pathway is the most extensively studied pathway in PCa because of its role in late-stage hormone-refractory PCa.”
BackgroundCrucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993 · cited 1×
“p53 deletion has been shown to synergize with Pten targeted inactivation (26) or Rb deficiency (27) to induce murine PCa, indicating that loss of p53 may play an important role in initiation and progression of PCa.”
BackgroundThe multistep nature of cancer
Vogelstein, B., & Kinzler, K. W. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90209-z · Cited by 1,853 · cited 1×
“H cancer is a multigene disorder in which several somatic mutations in cancer predisposition genes are required in a stepwise manner (1).”
BackgroundPurification and unique properties of mammary epithelial stem cells
Stingl, J., Eirew, P., Ricketson, I., Shackleton, M., Vaillant, F., Choi, D., Li, H. I., & Eaves, C. J. (2006) · Nature · doi:10.1038/nature04496 · Cited by 1,559 · cited 1×
“Previous studies in our lab showed that CD49f (integrin 6), a stem cell marker in multiple epithelial tissues (21, 22), was predominantly expressed on the basal surface of prostate basal cells and colocalized with its extracellular matrix ligand, laminin (22).”
BackgroundOncogenic Transcription Factors in the Human Acute Leukemias
Look, A. T. (1997) · Science · doi:10.1126/science.278.5340.1059 · Cited by 1,187
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134 · cited 2×
“With the promising progress in the development of PI3K inhibitors such as SF1126 and NVP-BEZ235 (42, 43) and more potent antiandrogen agents (44), strategies to specifically inhibit ETS transcription factors may be the critical component for combined target therapy in the treatment for ETS overexpressing PCa.”
BackgroundWang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109 · cited 1×
“Although activation of AKT in human PCa typically occurs through loss of PTEN, the activated AKT and Pten-deficient PCa mouse models demonstrate different degrees of disease progression, because constitutively active AKT only results in PIN lesion, whereas Pten deletion leads to metastatic PCa (32, 33).”
BackgroundDistinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844 · cited 2×
“1B), characterized by focal hypercellularity and increased epithelial tufting, which is consistent with the observations in ETV1 transgenic mice (8).”
BackgroundResult
Cited by
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
“ERG in transgenic mice and in a prostate tissue reconstitution model (Carver et al., 2009; King et al., 2009; Zong et al., 2009).”
BackgroundMolecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
“Furthermore , this overall approach can been greatly extended by efficient lentiviral infection of dissociated prostate epithelial cells, followed by tissue recombination, allowing for overexpression and knockdown approaches for analysis of gene function (Xin et al. 2003, 2006; Zong et al. 2009).”
BackgroundYu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
“…of a CMV-promoter driven AR (thus not susceptible to ERG repression, mimicking a hormone-refractory state with AR amplification), together with forced ERG overexpression, has recently been shown to promote the development of a more poorly differentiated, invasive adenocarcinoma (Zong et al., 2009).”
BackgroundIdentification of a Cell of Origin for Human Prostate Cancer
Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P., & Witte, O. N. (2010) · Science · doi:10.1126/science.1189992 · Cited by 554
Self-citationGenomic and biochemical insights into the specificity of ETS transcription factors
Hollenhorst, P. C., McIntosh, L. P., & Graves, B. J. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.79.081507.103945 · Cited by 490
“However, the genetic finding that ETS and AR genes cooperate in oncogenesis (175) indicates that this mechanism is more complex than our current understanding and may differ on a target-by-target basis (180).”
Metadata
- Authors
- Zong, Y., Xin, L., Goldstein, A. S., Lawson, D. A., Teitell, M. A., & Witte, O. N.
- Affiliations
- Howard Hughes Medical Institute (US)
- Department of Microbiology, Immunology, and Molecular Genetics,
- Molecular Biology Institute,
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-07-28
- Volume
- 106
- Issue
- 30
- Pages
- 12465-12470
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2708977
- OpenAlex
- W1963749564
- Cited by
- 203
- References
- 46
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 11 · 2018: 7 · 2017: 12 · 2016: 11 · 2015: 13 · 2014: 22 · 2013: 35 · 2012: 21
- FWCI
- 19.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Prostate Cancer Foundation
- Leukemia and Lymphoma Society
- National Cancer Institute (R00CA125937)
- National Institute of General Medical Sciences (GM-07185, T32GM007185)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- ETS transcription factors, ERG, prostate cancer, prostate tumorigenesis, prostatic intraepithelial neoplasia, epithelial hyperplasia, PI3K signaling, PTEN loss, Akt, androgen receptor, p53, tumor suppressor loss, adenocarcinoma differentiation, invasive carcinoma
- MeSH terms
- Transcriptional Regulator ERG, Red Fluorescent Protein, Animals, Cell Transformation, Neoplastic, Cells, Cultured, DNA-Binding Proteins, Epithelial Cells, Hyperplasia, Immunohistochemistry, Luminescent Proteins, Male, Mice, Inbred C57BL, Mutation, Prostate, Prostatic Neoplasms, Transcription Factors, Blotting, Western, Signal Transduction, Oncogene Proteins, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-myc, Proto-Oncogene Proteins c-jun, Prostatic Intraepithelial Neoplasia, Phosphatidylinositol 3-Kinases, Integrin alpha6, Proto-Oncogene Proteins c-ets, Mice, Keratin-5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. https://app.cochat.ai/papers/10.1073/pnas.0905931106
- The paper
- Zong, Y., Xin, L., Goldstein, A. S., Lawson, D. A., Teitell, M. A., & Witte, O. N. (2009). ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0905931106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.